AB SCIEX acquires mass spectrometry business of Labindia Instruments AB SCIEX, a global leader in life technology analytical technologies, announced that it has obtained the mass spectrometry business of Labindia Instruments Pvt today. Ltd., a leading life science solutions service provider in India uk pharmacy . This acquisition represents Stomach SCIEX’s increasing investment in India, combining its global resources, world-class scientific experience and product advancement leadership with well-established, local knowledge and on-site support to progress science and respond to the growing requirements of India’s scientific community. The changeover of this business, including customer relationships, personnel and application support facilities, to AB SCIEX is the result of the effective track record that Abdominal SCIEX and Labindia experienced as partners in India.
Considering the promising longer term efficacy observed in survival and safety from stage II, there is a compelling motive to execute a head-to-head comparison of masitinib against imatinib in first-line setting. On May 11th 2012, an Independent Data Monitoring Committee provided its positive opinion to keep this scholarly study. This potential, multicenter, randomized, open-label, active-managed, 2-parallel group, phase III study compares efficacy and safety of masitinib to the active control of imatinib in first-range treatment of patients with advanced GIST. This research will recruit around 200 patients from sites around the world, randomized with a 1:1 ratio between masitinib and imatinib.